Paroxysmal Nocturnal Hemoglobinuria at #ASH24

Maximizing Touchpoints to Empower Impactful Patient-Centered Care for Paroxysmal Nocturnal Hemoglobinuria

CME/CNE/CPE

Marriott Marquis San Diego

Friday, December 6, 2024 | 11:30 AM - 01:00 PM PT

Supported by independent funding from Novartis and by an independent educational grant from Alexion Pharmaceuticals, Inc.

overview

This interactive, live symposium will focus on all aspects of paroxysmal nocturnal hemoglobinuria (PNH) through the lens of the patient journey. Expert faculty will review the complement pathway, highlight diagnostic challenges, and discuss current and emerging treatment options, while listening to a patient share their experiences. A collaborative approach to patient care will be a key focus of the presentation as faculty prioritize care and quality of life for patients with PNH.

A Friday Satellite Symposium on Hematology, preceding the 66th ASH Annual Meeting and Exposition.

faculty

MODERATOR

Srikanth Nagalla, MD, MS

Chief of Benign Hematology

Miami Cancer Institute

Clinical Professor of Medicine

Herbert Wertheim College of Medicine

Florida International University

Miami, Florida, United States

Faculty

Christopher J. Patriquin, MD, MSc, FRCPC

Consultant, Hematology & Apheresis Medicine

Assistant Professor, University of Toronto  

Clinician Investigator, University Health Network

University Health Network -- Toronto General Hospital

Toronto, Ontario, Canada

AGENDA

11:00 am

Meal and Registration

11:30 am

Welcome and Introductions

11:35 am

The Patient’s Diagnostic Journey

11:40 am

Decoding PNH: Understanding the Complement Pathway

12:00 pm

The Patient’s Treatment Journey

12:05 pm

Diving Into the Data: Current and Future Directions in PNH Care

12:30 pm

The Patient’s Continued Journey

12:35 pm

Putting it All Together: Maximizing Touchpoints to Empower Impactful Patient-Centered Care for PNH

12:50 pm

Audience Q&A

GOAL STATEMENT

The goal of this activity is for learners to be better able to recognize the value of the patient voice to further improve the holistic care of patients with PNH.

TARGET AUDIENCE

This educational activity is intended for an audience of hematologists/oncologists, primary care physicians (PCPs), emergency medicine physicians, and other clinicians who treat patients with PNH in the United States.

LEARNING OBJECTIVES

Upon completion of this activity, participants will: [break] [break] Have increased knowledge regarding the[list][item]Evolving clinical data evaluating complement-based therapies for PNH[/list] [break] Have greater competence related to[list][item]Identifying patients with PNH in real-world clinical settings[item]Creating tailored care plans that include patient preferences, goals, and values[/list] [break] Demonstrate greater confidence in their ability to[list][item]Utilize effective communication strategies to develop individualized treatment plans that embrace patients' needs and empower shared decision-making (SDM)[/list]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

[bold]For Physicians[/bold][break] Medscape, LLC designates this live activity for a maximum of 1.5 [italic]AMA PRA Category 1 Credits[/italic]™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.[break] [break][bold]For Nurses[/bold][break] Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs.[break] [break][bold]For Pharmacists[/bold][break] Medscape designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number: JA0007105-0000-24-276-L01-P).